In the present study, two of these biomarkers, calreticulin (CRT) and triose phosphate isomerase (TPI), were recombinantly expressed and evaluated using experimental infection sera as candidates of a novel molecular test platform to measure TCBZ efficacy. The gene discussed is CALR; the disease is infection.